Enleofen Bio Pte

Enleofen is a biotechnology company focused on developing innovative therapies for fibrotic diseases. The company specializes in creating first-in-class antibody therapeutics that target the IL-11 pathway, a critical driver of fibrogenesis, organ dysfunction, and inflammation in various human fibrotic conditions. Enleofen serves the healthcare sector, particularly targeting patients suffering from fibrotic diseases such as non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs).

Operating primarily in the biopharmaceutical market, Enleofen's business model revolves around research and development (R&D) of novel therapeutics. The company generates revenue through partnerships and licensing agreements with larger pharmaceutical firms, such as Boehringer Ingelheim. These agreements often include upfront payments and milestone-based success fees, which can exceed one billion USD per product.

Enleofen was founded as a spin-out from NHCS, SingHealth, and Duke-NUS Medical School, leveraging cutting-edge research to transform the treatment landscape for fibro-inflammatory diseases. The company’s scientific advisory board comprises renowned experts in the field, ensuring robust and innovative therapeutic development.

Keywords: IL-11 pathway, fibrotic diseases, antibody therapeutics, NASH, ILDs, biopharmaceutical, R&D, licensing agreements, Singapore, Boehringer Ingelheim.